Skip to main content
SpringerLink
Log in

N-Terminal pro-B-Type Natriuretic Peptide

  • Chapter
Cardiac Markers

Part of the book series: Pathology and Laboratory Medicine ((PLM))

  • 178 Accesses

Abstract

The demonstration of specific granules in atrial muscle cells (1) and of the potent natriuretic, diuretic, and hypotensive response elicited by intravenous injection of atrial myocardial extract in rats (2) represent seminal, landmark findings in the era of cardiac natriuretic peptide research. During the past 20 yr remarkable scientific progress has been made, and by 2002 measurement of natriuretic peptides has been established as a valuable diagnostic and prognostic tool in clinical cardiology. Atrial or A-type natriuretic peptide (ANP) was purified, sequenced, and synthesized in the early 1980s (3,4), and the first report showing a natriuretic, diuretic, and vasodilatory effect of infusion of synthetic ANP in humans was published in 1985 (5). Within a short period of time several research groups reported that elevated plasma concentrations of ANP were found in patients with congestive heart failure (CHF) (6, 7). Moreover, a positive correlation between circulating ANP concentrations and atrial pressures was observed (8,9).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jamieson JD, Palade GE. Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151–172.

    Article  PubMed  CAS  Google Scholar 

  2. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89–94.

    Article  PubMed  Google Scholar 

  3. Atlas SA, Kleinert HD, Camargo MJ, . Purification, sequencing, and synthesis of natriuretic and vasoactive rat atrial peptide. Nature 1984; 309: 717–719.

    Article  PubMed  CAS  Google Scholar 

  4. Kangawa K, Matsuo H. Purification and complete amino acid sequence of a-human atrial natriuretic polypeptide (a-hANP). Biochem Biophys Res Commun 1984; 118: 131–139.

    Article  PubMed  CAS  Google Scholar 

  5. Richards AM, Nicholls MG, Ikram H, Webster MW, Yandle TG, Espiner EA. Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985; 1: 545–549.

    Article  PubMed  CAS  Google Scholar 

  6. Sugawara A, Nakao K, Morii N, . Alpha-human atrial natriuretic polypeptide is released from the heart and circulates in the body. Biochem Biophys Res Commun 1985; 129: 439–446.

    Article  PubMed  CAS  Google Scholar 

  7. Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T. Atrial natriuretic factor-a circulating hormone stimulated by volume loading. Nature 1985; 314: 264–266.

    Article  PubMed  CAS  Google Scholar 

  8. Raine AEG, Erne P, Bürgisser E, . Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986; 315: 533–537.

    Article  PubMed  CAS  Google Scholar 

  9. Burnett JC Jr, Kao PC, Hu DC, . Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145–1147.

    Article  PubMed  Google Scholar 

  10. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78–81.

    Article  PubMed  CAS  Google Scholar 

  11. Mukoyama M, Nakao K, Hosoda K, . Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402–1412.

    Article  PubMed  CAS  Google Scholar 

  12. Levin ER, Gardner DG, Samson WK. Natriuretic peptides (review). N Engl J Med 1998; 339: 321–328.

    Article  PubMed  CAS  Google Scholar 

  13. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988; 62: 191–195.

    Article  PubMed  CAS  Google Scholar 

  14. Magga J, Vuolteenaho O, Tokola H, Marttila M, Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression (review). Ann Med 1998; 30 (Suppl 1): 39–45.

    PubMed  CAS  Google Scholar 

  15. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metabol 1988; 66: 605–610.

    Article  CAS  Google Scholar 

  16. Vesely D, Douglass MA, Dietz JR, . Three peptides from the atrial natriuretic factor pro-hormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994; 90: 1129–1140.

    Article  PubMed  CAS  Google Scholar 

  17. Thibault G, Murthy K, Gutkowska J, . NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides 1988; 9: 147–153.

    Google Scholar 

  18. Mathisen P, Hall C, Simonsen S. Comparative study of atrial peptides ANF (1–98) and ANF (99–126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1991; 53: 41–49.

    Article  Google Scholar 

  19. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76: 832–838.

    Article  PubMed  CAS  Google Scholar 

  20. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995; 214: 1175–1183.

    Article  PubMed  CAS  Google Scholar 

  21. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG.. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997; 18: 1475–1481.

    Article  PubMed  CAS  Google Scholar 

  22. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287–296.

    Article  CAS  Google Scholar 

  23. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand. J Clin Lab Invest 2001; 61: 33–42.

    Article  CAS  Google Scholar 

  24. Cowie MR, Mosterd A, Wood DA, . The epidemiology of heart failure. Eur Heart J 1997; 18: 208–225.

    Article  PubMed  CAS  Google Scholar 

  25. Dargie H J, McMurray JJ, McDonagh TA. Heart failure-implications of the true size of the problem. J Intern Med 1996; 239: 309–315.

    Article  PubMed  CAS  Google Scholar 

  26. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–306.

    Article  PubMed  CAS  Google Scholar 

  27. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315–321.

    Article  PubMed  CAS  Google Scholar 

  28. McDonagh TA, Morrison CE, Lawrence A, . Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829–833.

    Article  PubMed  CAS  Google Scholar 

  29. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.

    Article  Google Scholar 

  30. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36: 355–359.

    Article  PubMed  CAS  Google Scholar 

  31. Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999; 20: 1736–1744.

    Article  PubMed  CAS  Google Scholar 

  32. Hammerer-Lercher A, Neubauer E, Müller S, Pachinger 0, Puschendor B, Mair J. Headto-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310: 193–197.

    CAS  Google Scholar 

  33. McDonagh TA, Morton JJ, Baumann M, Trawinski J, Dargie HJ. N-terminal pro BNP: role in the diagnosis of left ventricular dysfunction in a population-based study (abstract). J Cardiac Fail 2000; 6 (Abstr Suppl 2): 23.

    Google Scholar 

  34. Grenning BA, Raymond I, Pedersen F, . N-terminal pro brain natriuretic peptide concentrations in the diagnosis of heart failure in the general population (abstract). Eur J Heart Fail 2000;3(Suppl 1):Abstr 95.

    Google Scholar 

  35. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–1130.

    Article  PubMed  CAS  Google Scholar 

  36. McDonagh TA, Baumann M, Trawinski J, Morton JJ, Dargie HJ. N-terminal pro BNP and prognosis of left ventricular dysfunction in a population-based study (abstract). Circulation 2000; 102 (Abstr Suppi): II - 845.

    Google Scholar 

  37. Richards AM, Doughty R, Nicholls MG, . Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in ischemic left ventricular dysfunction. J Am Coll Cardiol 2001; 37: 1781–1787.

    Article  PubMed  CAS  Google Scholar 

  38. Richards AM, Nicholls MG, Yandle TG, . Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921–1929.

    Article  PubMed  CAS  Google Scholar 

  39. Omland T, Samuelsson A, Richards AM, . Plasma N-terminal pro-brain natriuretic peptide in acute myocardial infarction. In: Proceedings of the XIII World Congress of Cardiology, Rio de Janeiro, Brasil, 1998, pp. 181–185.

    Google Scholar 

  40. Talwar S, Squire IB, Downie PF, . Profile of plasma NT-proBNP following acute myocardial infarction. Correlation with left ventricular dysfunction. Eur Heart J 2000; 21: 1514–1521.

    Article  PubMed  CAS  Google Scholar 

  41. Omland T, de Lemos JA, Morrow DA, . Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89: 463–465.

    Article  PubMed  CAS  Google Scholar 

  42. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin-1 are raised in unstable angina. Heart 2000; 84: 421–424.

    CAS  Google Scholar 

  43. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal proBNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001; 3: 15–19.

    Article  PubMed  CAS  Google Scholar 

  44. Qi W, Mathisen P, Kjekshus J, . Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725–732.

    Article  PubMed  CAS  Google Scholar 

  45. Luchner A, Hengstenberg C, Lowell H, . N-terminal pro-brain natriuretic peptide after myocardial infarction. A marker of cardio-renal function. Hypertension 2002; 39: 99–104.

    Article  PubMed  CAS  Google Scholar 

  46. Wang TJ, Levy D, Leip EP, . Determinants of natriuretic peptide levels in a healthy population and derivation of reference limits (abstract). Circulation 2001; 104 (Abstr Suppl): II - 189.

    Google Scholar 

  47. Talwar S, Siebenhofer A, Williams B, Ng LL. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N-terminal proBNP. Heart 2000; 83: 278–282.

    Article  PubMed  CAS  Google Scholar 

  48. Muders F, Eckhard EP, Griese DP, . Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442–449.

    Article  PubMed  CAS  Google Scholar 

  49. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelia, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997; 36: 246–255.

    Article  PubMed  CAS  Google Scholar 

  50. Yandle T, Fisher S, Espiner E, Richards AM, Nicholls G. Validating aminoterminal BNP assays: a word of caution. Lancet 1999; 353: 1068.

    Article  PubMed  CAS  Google Scholar 

  51. Hughes D, Talwar S, Squire IB, Davies JE, Ng LL. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci (Colch) 1999; 96: 373–380.

    Article  CAS  Google Scholar 

  52. Karl J, Borgya A, Galluser A, . Development of a novel, N-terminal proBNP (NT-proBNP) assay with a lower detection limit. Scand J Clin Lab Invest 1999; 59: 177–181.

    CAS  Google Scholar 

  53. Missbichler A, Hawa G, Woloszczuk W, Schmal N, Hartter E. Enzyme immunoassays for proBNP fragments (8–29) and (32–57). J Lab Med 1999; 23: 241–244.

    CAS  Google Scholar 

  54. http://www.roche.com/ diagnostics/news/2002/020128.html

    Google Scholar 

  55. Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Colch) 1999; 97: 255–258.

    Article  CAS  Google Scholar 

  56. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002; 87: 131–135.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Torbjørn Omland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA

    Alan H. B. Wu PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Omland, T., Hall, C. (2003). N-Terminal pro-B-Type Natriuretic Peptide. In: Wu, A.H.B. (eds) Cardiac Markers. Pathology and Laboratory Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-385-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-385-9_26

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-319-0

  • Online ISBN: 978-1-59259-385-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation